Summary
Oncogenic mutations in two isocitrate dehydrogenase
(IDH)-encoding genes (IDH1 and
IDH2) have been identified in acute myelogenous leukemia,
low-grade glioma, and secondary glioblastoma (GBM). Our in
silico and wet-bench analyses indicate that non-mutated IDH1 mRNA
and protein are commonly overexpressed in primary GBM. We show that genetic and
pharmacologic inactivation of IDH1 decreases GBM cell growth, promotes a more
differentiated tumor cell state, increases apoptosis in response to targeted
therapies, and prolongs survival of animal subjects bearing patient-derived
xenografts (PDXs). On a molecular level, diminished IDH1 activity results in
reduced α-ketoglutarate (αKG) and NADPH production, paralleled
by deficient carbon flux from glucose or acetate into lipids, exhaustion of
reduced glutathione, increased levels of reactive oxygen species (ROS), and
enhanced histone methylation and differentiation marker expression. These
findings suggest that IDH1 upregulation represents a common metabolic adaptation
by GBM to support macromolecular synthesis, aggressive growth, and therapy
resistance.